| Poster Number |
Title of Presentation |
Presenter Name |
| 1 |
Addressing HIV/HCV Co-Infection among Injecting Drug Users in Jakarta, Indonesia using Peer Driven Intervention |
Edo Agustian |
| 2 |
Circumstances around First Drug Injection and Prevalence of HIV, Hepatitis B (HBV) and Hepatitis C (HCV) Among Participants of a Needle Exchange Program (NEP) |
Marianne Alanko Blomé |
| 3 |
Cause-Specific Mortality among People with a Hepatitis C Notification: A Population-Based Linkage Study, 1993-2012 |
Maryam Alavi |
| 4 |
Reduced HCV Recurrent Viremia in PWID with Treatment Induced Virologic Clearance through a Comprehensive Multidisciplinary Treatment Model |
Arshia Alimohammadi |
| 5 |
Hepatitis B Virus (HBV) Serological Status among People Who Enter the Opioid Substitution Programme in Greece |
Olga Anagnostou |
| 6 |
Incidence and Predictors of Hepatitis C Treatment Initiation among People who Inject Drugs: Longitudinal Data from a Greek Tertiary Center, 2009-2015. |
Olga Anagnostou |
| 7 |
Low-Threshold Hepatitis C Treatment for People Who Inject Drug – How to Ensure Compliance and Treatment Success |
Øystein Backe/Kristin Vennesland |
| 8 |
Modelling Hepatitis C Virus Transmission in a High-Risk Incarcerated Population |
Neil Bretana |
| 9 |
HCV Treatment Initiation among HCV Infected PWID in Capica, A Retrospective Study in Twelve Canadian Clinical Settings |
Julie Bruneau |
| 10 |
Heroin Assisted Treatment Setting: Feasibility and Efficacy of Hepatitis C DAA Treatment |
Nathalie Brunner |
| 11 |
Hepatitis C Testing in the General Practice Setting for Australians Who Inject Drugs |
Kerryn Butler |
| 12 |
Hepatitis C Virus RNA Quantification on Dry Capillary Blood Spot |
Erika Castro |
| 13 |
DAA 2nd Generation Treatment Outcome in Substance Users |
Erika Castro |
| 14 |
Attitudes towards Hepatitis C and Treatment Willingness among People Who Inject Drugs: A Follow-Up Interview Study |
Disa Dahlman |
| 15 |
Stage of Liver Disease in Hepatitis C Patients at a Low-Threshold Hepatitis C Clinic in Oslo |
Olav Dalgard |
| 16 |
High Hepatitis C Virus Reinfection Rate after Achieving Sustained Virological Response (Svr) among People who Inject Drugs Actively: Tactic Cohort |
Lucie Deshaies |
| 17 |
Trends In Hepatocellular Carcinoma Among People Receiving Opioid Substitution Therapy With an HCV Notification In New South Wales, Australia Between 2000 and 2014 |
Greg Dore |
| 18 |
Baseline Characteristics and Recruitment in a Randomised Trial of Community Vs Hospital Direct Acting Antiviral Treatment for Hepatitis C |
Joseph Doyle |
| 19 |
Eliminating Hepatitis C Transmission by Enhancing Care and Treatment among HIV Co-Infected Individuals: The Co-EC Study |
Joseph Doyle |
| 20 |
Experiences of alcohol use and hepatitis c among people who inject drugs: implications for treatment services. |
Jane Evely |
| 21 |
HCV Capacity Building Trainings for Harm Reduction and Peer Workers |
Jason Farrell |
| 22 |
High Rates of Sustained Virological Response in People Who Inject Drugs Treated With Sofosbuvir-Based Regimens in Ukraine |
Sergii Filippovych |
| 23 |
Intermittent Injecting Drug Use and HCV Incidence in an Observational Cohort Study of People Who Inject Drugs in Montréal, Canada |
Emmanuel Fortier |
| 24 |
Scaling Up HCV Treatment, Syringe Services and Medicated-Assisted Treatment for Achieving Rapid HCV Elimination in Rural America – Model Projections For Indiana |
Hannah Fraser |
| 25 |
Real World Experience in HCV Awareness, Testing, Care and Knowledge Transfer in La Ronge, Saskatchewan |
Lesley Gallagher |
| 26 |
Past Incarceration Experience and the Risk of Hepatitis C Infection among People Who Inject Drugs: Results from a Sero-Behavioral Survey among Current Injectors in Germany |
Martyna Gassowski |
| 27 |
Efficacy of Sofosbuvir/Ledipasvir With and Without Ribavirin in Patients with Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials |
Jason Grebely |
| 28 |
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials |
Jason Grebely |
| 29 |
Efficacy of All-Oral HCV Therapy in People who Inject Drugs |
Syune Hakobyan |
| 30 |
Portable Pop-Up Clinics: Characteristics of Engagement in Care, an Observational Prospective Cohort Study |
Syune Hakobyan |
| 31 |
Analysis of Adherence to All-Oral HCV Therapy in a Cohort of People Who Inject Drugs (PWID) |
Syune Hakobyan |
| 32 |
Direct observed therapy of Chronic Hepatitis C with Interferon-Free All-Oral regimens at a Low-Threshold Drug Treatment facility – A new concept for treatment of patients with Borderline Compliance receiving Opioid Substitution Therapy |
Hans Haltmayer |
| 33 |
Peer Support for People Living with Hepatitis C in Drug and Alcohol Settings Increases Hep C Assessment and Knowledge |
Mary Harrod |
| 34 |
Ethical Research and Engagement with People Who Use Drugs: Frameworks and Implementation |
Mary Harrod |
| 35 |
Geographic Determinants of Hepatitis C Screening in a Mixed Urban/Rural Epidemic |
Karli Hochstatter |
| 36 |
Hepatitis C Testing and Undiagnosed Infections among People Injecting Image and Performance Enhancing Drugs in England & Wales: 2012-15. |
Vivian Hope |
| 37 |
Factors Associated with Entry into Healthcare Pathways for Hepatitis C among People who Inject Psychoactive Drugs in the United Kingdom (UK) |
Vivian Hope |
| 38 |
Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia |
Jenny Iversen |
| 39 |
Infcare Needle Syringe Program (Infcare NSP), A Database for following and Reducing Injection Risk Behavior Over Time in PWID in Stockholm |
Martin Kåberg |
| 40 |
Pre-Testing Knowledge of Hepatitis C Status among 1504 Consecutive Participants at the Stockholm Needle Exchange |
Martin Kåberg |
| 41 |
Does Chronic Hepatitis C Cause Fatigue? |
Knut Boe Kielland |
| 42 |
Injecting Drug Use Among Inmate in Norwegian Prisons |
Knut Boe Kielland |
| 43 |
Aggressive Treatment of Hepatitis C in People Who Inject Drugs in Norway: An Integral Step to Eradicate the Infection in this Population |
Knut Boe Kielland |
| 44 |
The Hep-NORDIC project: viral hepatitis C managemnet policies for people who inject drugs in the five Nordic countries |
Jeffrey Lazarus |
| 45 |
Modelling the Impact of Interventions Targeting High-Risk Populations on the HCV Epidemic in Pakistan |
Aaron Lim |
| 46 |
Impact of HCV Advocacy and Demonstration Treatment Programs Specifically Targeted at PWIDS on National Hepatitis Policy |
Ludmila Maistat |
| 47 |
A Qualitative Study of the Perceptions of Interferon-Free Therapy for Hepatitis C Virus Infection among People Who Inject Drugs: The Liver life Study |
Alison Marshall |
| 48 |
Substantial Decline of Hepatitis C Virus Prevalence among PWID in Flanders, Belgium: The Result of a Comprehensive Approach |
Catharina Matheï |
| 49 |
Earth Study (Phase 1): Expanding Access to Rapid Treatment for Hep C |
Dee Menezes |
| 50 |
Reinfection of Hepatitis C among People Who Inject Drugs in Norway: Opportunity for Intervention-A Modelling Study |
Havard Midgard |
| 51 |
Improved Access to HCV Treatment for Substance Users: The Impact of On-Site Transient Elastography in an Inner City Community Health Centre |
Rozalyn Milne |
| 52 |
Prospective Data on People Who Use Drugs in Switzerland: The SAMMSU Cohort |
Alberto Moriggia |
| 53 |
High Prevalence of Liver Fibrosis among People Attending Addiction Clinics and Rehabilitation Facilities in Southern Switzerland: Results of Two Different Screening Programs for Liver Disease |
Alberto Moriggia |
| 54 |
Development and Validation of a Novel Measurement Scale for Interpersonal Factors Underlying Injection Drug Using Behaviors |
Meghan Morris |
| 55 |
Dried Blood Spot, Valid Screening Method for Viral Hepatitis and HIV in Real-Life |
Belinda Klemmensen Mössner |
| 56 |
Low Levels of HCV Awareness and Risk Among Groups Most at Risk in Vietnam |
Huong Ngo |
| 57 |
Concordance between Self-Reported and Measured HIV and Hepatitis C Virus Infection Status among People Who Inject Drugs in Germany |
Stine Nielsen |
| 58 |
Are There Missed Opportunities for Vaccinating Against Hepatitis B among People Who Inject Drugs (PWID) in the United Kingdom (UK)? |
Jacquelyn Njoroge |
| 59 |
Dot-C: A Pilot Trial of Directly Observed Anti HCV Therapy in a Population Receiving Opiate Substitution Therapy (OST) from a Pharmacy - Uptake of Testing Results |
Andrew Radley |
| 60 |
Adherence to Hepatitis C Treatment Regimen among People Who Inject Drugs in Norway: Implications for Treatment Strategies |
Devin-Razavi Shearer |
| 61 |
Compass Project, Inside and Outside Link for Prisoners and PWID with Hepatitis C in France |
Andre Jean Remy |
| 62 |
Global Genotype Distribution of Hepatitis C Viral Infection among People who Inject Drugs |
Geert Robaeys |
| 63 |
Hepatitis C Treatment on PWUD in the DAA’S Era: High Rate of Virological Response in the Real Life |
Antonella Robatto |
| 64 |
Trends of Hepatitis C Virus Epidemic in Australia and North America in 20th Century: Back Projections from Molecular Epidemiology |
Chaturaka Rodrigo |
| 65 |
Drug Market Variations and Drug Use Practices among People Who Inject Drugs in the Province of Québec, Canada |
Élise Roy |
| 66 |
Hepatitis C and Risk Behavior among Persons Who Inject Drugs in Norway |
Rikard Rykkvin |
| 67 |
The Efficacy of Psychosocial Interventions to Reduce Sexual and Drug Blood Borne Virus Risk Behaviours among People Who Inject Drugs: A Systematic Review and Meta-Analysis |
Davina Swan |
| 68 |
Training Drug Users in Overdose Reversal with Intranasal Naloxone – A New Approach to Address Opioid Overdoses and other General Health Problems |
Henrik Thiesen |
| 69 |
The Effects of Alcohol on Spontaneous Clearance of Acute Hepatitis C Virus Infection in Females versus Males Who Inject Drugs |
Judith Tsui |
| 70 |
Feasibility and Efficacy of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Infection in a Low Threshold Setting |
Kjersti Ulstein |
| 71 |
Prevalence and Determinants of Liver Disease among People who use Drugs in Amsterdam, The Netherlands |
Daniela van Santen |
| 72 |
From the Users' Perspective - An interview Study with Peoplw who Inject Drugs on the Usefulness of Participating in a Needle Syrimge Program |
Malin Varma Falk |
| 73 |
Impact of Current and Scaled Up Levels of Needle and Syringe Programmes and Opiate Substitution Therapy in Three UK Settings |
Zoe Ward |
| 74 |
C-Buddies: Missing Piece of the Puzzle in a Comprehensive “Not Under One Roof“. Approach for Hepatitis C Management Among People Who Use Drugs . |
Tessa Windelinckx |
| 75 |
Integrating a Hepatitis C Peer Support Worker in a Public Drug Treatment Clinic |
Vicci Goodwin |
